Extemporaneous combination therapy with nebivolol/valsartan for the treatment of hypertension: a study of real-world evidence in Europe

References

• World Health Organization. High blood pressure: a public health problem [cited 2022 Jun 1]. Available from: http://www.emro.who.int/media/world-health-day/public-health-problem-factsheet-2013.html.
   Google Scholar
• Tocci G, Muiesan ML, Parati G, et al. Trends in prevalence, awareness, treatment, and control of blood pressure recorded from 2004 to 2014 during world hypertension day in Italy. J Clin Hypertens. 2016;18(6):551–556.
   PubMed Web of Science ®Google Scholar
• Tocci G, Nati G, Cricelli C, et al. Prevalence and control of hypertension in the general practice in Italy: updated analysis of a large database. J Hum Hypertens. 2017;31(4):258–262. doi: 10.1038/jhh.2016.71.
   PubMed Web of Science ®Google Scholar
• Levi M, Pasqua A, Cricelli I, et al. Patient adherence to olmesartan/amlodipine combinations: fixed versus extemporaneous combinations. J Manag Care Spec Pharm. 2016;22(3):255–262.
   PubMedGoogle Scholar
• Mennini FS, Marcellusi A, von der Schulenburg JMG, et al. Cost of poor adherence to anti-hypertensive therapy in five european countries. Eur J Health Econ. 2015;16(1):65–72. doi: 10.1007/s10198-013-0554-4.
   PubMed Web of Science ®Google Scholar
• Williams B, Mancia G, Spiering W, et al. 2018 ESC/ESH guidelines for the management of arterial hypertension. Eur Heart J. 2018;39(33):3021–3104. doi: 10.1093/eurheartj/ehy339.
   PubMed Web of Science ®Google Scholar
• Münzel T, Gori T. Nebivolol: the somewhat-different beta-adrenergic receptor blocker. J Am Coll Cardiol. 2009;54(16):1491–1499. doi: 10.1016/j.jacc.2009.05.066.
   PubMed Web of Science ®Google Scholar
• Hayek SS, Poole JC, Neuman R, et al. Differential effects of nebivolol and metoprolol on arterial stiffness, circulating progenitor cells, and oxidative stress. J Am Soc Hypertens. 2015;9(3):206–213.
   PubMed Web of Science ®Google Scholar
• Black HR, Bailey J, Zappe D, et al. Valsartan: more than a decade of experience. Drugs. 2009;69(17):2393–2414. doi: 10.2165/11319460-000000000-00000.
   PubMed Web of Science ®Google Scholar
• Mistry NB, Westheim AS, Kjeldsen SE. The angiotensin receptor antagonist valsartan: a review of the literature with a focus on clinical trials. Expert Opin Pharmacother. 2006;7(5):575–581. doi: 10.1517/14656566.7.5.575.
   PubMed Web of Science ®Google Scholar
• Sander GE, Giles TD. Nebivolol and valsartan as a fixed-dose combination for the treatment of hypertension. Expert Opin Pharmacother. 2015;16(5):763–770. doi: 10.1517/14656566.2015.1020790.
   PubMed Web of Science ®Google Scholar
• Varagic J, Punzi H, Ferrario CM. Clinical utility of fixed-dose combinations in hypertension: evidence for the potential of nebivolol/valsartan. Integr Blood Press Control. 2014;7:61–70. doi: 10.2147/IBPC.S50954.
   PubMedGoogle Scholar
• Giles TD, Weber MA, Basile J, et al. Efficacy and safety of nebivolol and valsartan as fixed-dose combination in hypertension: a randomised, multicentre study. Lancet. 2014;383(9932):1889–1898.
   PubMed Web of Science ®Google Scholar
• Volpe M, Pegoraro V, Heiman F, et al. Extemporaneous combination therapy with amlodipine/zofenopril in hypertensive patients: a real-world data analysis in Italy. Curr Med Res Opin. 2023;39(12):1593–1601.
   PubMed Web of Science ®Google Scholar
• Volpe M, Pegoraro V, Peduto I, et al. Extemporaneous combination therapy with nebivolol/zofenopril in hypertensive patients: usage in Italy. Curr Med Res Opin. 2022;38(10):1673–1681. doi: 10.1080/03007995.2022.2096352.
   PubMed Web of Science ®Google Scholar
• IQVIA. Osservatorio sull’impatto della pandemia COVID-19 sull’accesso alle cure. Periodo dati: 2019–2020; 2021 Available from: https://www.farmindustria.it/app/uploads/2021/03/Osservatorio-IQVIA-sullimpatto-pandemia-sullaccesso-alle-cure_Marzo-2021.pdf.
   Google Scholar
• Prieto-Merino D, Mulick A, Armstrong C, et al. Estimating proportion of days covered (PDC) using real-world online medicine suppliers’ datasets. J Pharm Policy Pract. 2021;14(1):113.
   PubMed Web of Science ®Google Scholar
• Wang SJ, Sander GE. Nebivolol/valsartan combination for the treatment of hypertension: a review. Future Cardiol. 2021;17(4):573–583. doi: 10.2217/fca-2020-0079.
   PubMed Web of Science ®Google Scholar
• Farag SM, Rabea HM, Mahmoud HB. Effect of amlodipine/valsartan versus nebivolol/valsartan fixed dose combinations on peripheral and central blood pressure. High Blood Press Cardiovasc Prev. 2018;25(4):407–413. doi: 10.1007/s40292-018-0286-8.
   PubMedGoogle Scholar
• Ishak J, Rael M, Punzi H, et al. Additivity of nebivolol/valsartan single-pill combinations versus other single-pill combinations for hypertension. J Clin Hypertens. 2018;20(1):143–149.
   PubMed Web of Science ®Google Scholar
• Mende CW, Giles TD, Bharucha DB, et al. Efficacy of nebivolol-valsartan single-pill combination in obese and nonobese patients with hypertension. J Clin Hypertens. 2017;19(6):632–639. doi: 10.1111/jch.12965.
   Web of Science ®Google Scholar
• Schmieder RE, Wassmann S, Predel H-G, et al. Improved persistence to medication, decreased cardiovascular events and reduced all-cause mortality in hypertensive patients with use of single-pill combinations: results from the START-study. Hypertension. 2023;80(5):1127–1135. doi: 10.1161/HYPERTENSIONAHA.122.20810.
   PubMed Web of Science ®Google Scholar
• Mancia G, Volpe R, Boros S, et al. Cardiovascular risk profile and blood pressure control in Italian hypertensive patients under specialist care. J Hypertens. 2004;22(1):51–57.
   PubMed Web of Science ®Google Scholar
• Rea F, Savaré L, Franchi M, et al. Adherence to treatment by initial antihypertensive Mono and combination therapies. Am J Hypertens. 2021;34(10):1083–1091. doi: 10.1093/ajh/hpab083.
   PubMed Web of Science ®Google Scholar
• Conn VS, Ruppar TM, Chase JA, et al. Interventions to improve medication adherence in hypertensive patients: systematic review and meta-analysis. Curr Hypertens Rep. 2015;17(12):94. doi: 10.1007/s11906-015-0606-5.
   PubMed Web of Science ®Google Scholar
• Peacock E, Krousel-Wood M. Adherence to antihypertensive therapy. Med Clin North Am. 2017;101(1):229–245. doi: 10.1016/j.mcna.2016.08.005.
   PubMed Web of Science ®Google Scholar
• Hypertension EETFftMoA. 2013 Practice guidelines for the management of arterial hypertension of the European Society of Hypertension (ESH) and the European Society of Cardiology (ESC): ESH/ESC task force for the management of arterial hypertension. J Hypertens. 2013;31(10):1925–1938.
   PubMed Web of Science ®Google Scholar
• Unger T, Borghi C, Charchar F, et al. 2020 International society of hypertension global hypertension practice guidelines. J Hypertens. 2020;38(6):982–1004. doi: 10.1097/HJH.0000000000002453.
   PubMed Web of Science ®Google Scholar
• Hypertension Canada. Guidelines-Hypertension Canada [cited 2022 Jun 7]. Available from: https://guidelines.hypertension.ca/chep-resources/.
   Google Scholar
• Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology/American Heart Association Task Force on clinical practice guidelines. J Am Coll Cardiol. 2018;71(19):e127–e248. doi: 10.1016/j.jacc.2017.11.006.
   PubMed Web of Science ®Google Scholar
• Düsing R, Waeber B, Destro M, et al. Triple-combination therapy in the treatment of hypertension: a review of the evidence. J Hum Hypertens. 2017;31(8):501–510. doi: 10.1038/jhh.2017.5.
   PubMed Web of Science ®Google Scholar
• Camm AJ, Fox KAA. Strengths and weaknesses of 'real-world’ studies involving non-vitamin K antagonist oral anticoagulants. Open Heart. 2018;5(1):e000788. doi: 10.1136/openhrt-2018-000788.
   PubMedGoogle Scholar
• Forzano I, Mone P, Varzideh F, et al. The selective aldosterone synthase inhibitor baxdrostat significantly lowers blood pressure in patients with resistant hypertension. Front Endocrinol. 2022;13:1097968. doi: 10.3389/fendo.2022.1097968.
   PubMed Web of Science ®Google Scholar
• Trimarco V, Izzo R, Mone P, et al. Therapeutic concordance improves blood pressure control in patients with resistant hypertension. Pharmacol Res. 2023;187:106557. doi: 10.1016/j.phrs.2022.106557.
   PubMed Web of Science ®Google Scholar